2,2-Bis-(hydroxymethyl)cyclopropylidenemethyl-Purines and -Pyrimidines As Antiviral Agents

Abstract

Compounds which are active against viruses have the following formulas: wherein B is a purine or pyrimidine heterocyclic ring or base. In a preferred embodiment, the purine include 6-aminopurine (adenine), 6-hydroxypurine (hypoxanthine), 2-amino-6-hydroxypurine (guanine), 2,6-diamino-purine, 2-amino-6-azidopurine, 2-amino-6-halo substituted purines such as 2-amino-6-chloropurine, 2-amino-6-fluoropurine, 2-amino-6-alkoxypurines such as 2-amino-6-methoxypurine, 2-amino-6-cyclopropylaminopurine, 2-amino-6-alkylamino or 2-amino-6-dialkylamino substituted purines, 2-amino-6-thiopurine, 2-amino-6-alkylthio substituted purines, 3-deazapurines, 7-deazapurines and 8-azapurines. The pyrimidine incorporates cytosine, uracil and thymine, 5-halo substituted cytosines and uracils, 5-alkyl substituted cytosines and uracils including derivatives with a saturated or unsaturated alkyl group and 6-azapyrimidines.

1 . A compound having the formula: 
     
       
         
         
             
             
         
       
     
     wherein B is a 3-deazapurine, 7-deazapurine, 8-azapurine, or pyrimidine, and pharmaceutically acceptable salts and prodrugs thereof. 
   
   
       2 . The compound of  claim 1 , wherein B is selected from the group consisting of 3-deazapurines, 7-deazapurines, and 8-azapurines. 
   
   
       3 . The compound of  claim 1 , wherein the pyrimidine is selected from the group consisting of cytosine 5-halo substituted cytosines (wherein halo is fluoro, chloro, bromo, or iodo), thymines, uracils, 5-alkyl or alkenyl uracils, and 6-azapyrimidines. 
   
   
       4 . The compound of  claim 1 , wherein the compound is selected from the group consisting of (Z)-1-{[2,2-bis-(hydroxymethyl)cyclo-propylidene]methyl}cytosine (1e), (z)-1-{[2,2-bis-(hydroxymethyl)cyclo-propylidene]methyl}thymine (1f), (E)-1-{[2,2-bis-(hydroxymethyl)cyclo-propylidene]methyl}cytosine (2e) and (E)-1-{[2,2-bis-(hydroxymethyl)cyclo-propylidene]methyl}thymine (2f). 
   
   
       5 . (canceled) 
   
   
       6 . A composition comprising a compound of any one of  claims 1 - 4  and a pharmaceutically acceptable carrier. 
   
   
       7 . A method of treating of a mammal infected with a virus selected from the group consisting of HHV, VZV, HCMV, EBV, HSV-1 and HSV-2, comprising a step of administering to said mammal a compound according to any one of  claims 1 - 4  and combinations thereof. 
   
   
       8 . The method of  claim 7 , wherein said mammal is a human. 
   
   
       9 . (canceled) 
   
   
       10 . The method of  claim 7 , further comprising a step of administering an additional compound. 
   
   
       11 . The method of  claim 10 , wherein said additional compound is selected from the group consisting of acyclovir, ganciclovir, zidovudine, AZT, ddl, ddc, 3TC, d4T, foscamet, cidofovir, fomivirsen, and combinations thereof.